Cancer clinical trials cooperative groups are in jeopardy, and changes are needed to enable the system to survive, chairmen of the groups wrote in a paper submitted to NCI. White paper makes 25 recommendations, including changing system incentives, review process, group integration with centers and SPOREs, and inclusion in CaBIG. This 8-page issue includes full text of the white paper.
Also New AACR President Lynn Matrisian plans emphasis on enhancing communication.
Peter Jones begins term as AACR president-elect. New directors elected.
AACR honors Emil Frei III for pioneering work in childhood leukemia.
Trending Stories
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- Pour a Scotch, we’re talking clinical trials and prediction markets
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home
- Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns
